Johnson & Johnson forecasts as much as 6% sales growth in 2024
Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti.
Source link
Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti.
Source link
